Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Enanta Pharmaceuticals (ENTA) Non-cash Items (2016 - 2025)

Historic Non-cash Items for Enanta Pharmaceuticals (ENTA) over the last 14 years, with Q3 2025 value amounting to $6.5 million.

  • Enanta Pharmaceuticals' Non-cash Items rose 35600.28% to $6.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $6.5 million, marking a year-over-year increase of 35600.28%. This contributed to the annual value of $6.5 million for FY2025, which is 35600.28% up from last year.
  • According to the latest figures from Q3 2025, Enanta Pharmaceuticals' Non-cash Items is $6.5 million, which was up 35600.28% from $92000.0 recorded in Q2 2025.
  • Over the past 5 years, Enanta Pharmaceuticals' Non-cash Items peaked at $83.0 million during Q1 2022, and registered a low of $2000.0 during Q2 2023.
  • Over the past 5 years, Enanta Pharmaceuticals' median Non-cash Items value was $3.6 million (recorded in 2024), while the average stood at $14.8 million.
  • As far as peak fluctuations go, Enanta Pharmaceuticals' Non-cash Items tumbled by 9999.0% in 2023, and later surged by 16135000.0% in 2024.
  • Enanta Pharmaceuticals' Non-cash Items (Quarter) stood at $2.4 million in 2021, then grew by 10.72% to $2.7 million in 2022, then increased by 12.77% to $3.0 million in 2023, then rose by 14.17% to $3.5 million in 2024, then skyrocketed by 86.78% to $6.5 million in 2025.
  • Its Non-cash Items was $6.5 million in Q3 2025, compared to $92000.0 in Q2 2025 and $3.6 million in Q1 2025.